A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 23, 2022

Primary Completion Date

November 15, 2022

Study Completion Date

December 13, 2022

Conditions
Sarcoidosis, Cardiac
Interventions
DRUG

Namilumab

Specified dose on specified days

Trial Locations (12)

10029

Kinevant Study Site, New York

21234

Kinevant Study Site, Baltimore

29425

Kinevant Study Site, Charleston

32610

Kinevant Study Site, Gainesville

44195

Kinevant Study Site, Cleveland

48109

Kinevant Study Site, Ann Arbor

52242

Kinevant Study Site, Iowa City

80206

Kinevant Study Site, Denver

94304

Kinevant Study Site, Palo Alto

97239

Kinevant Study Site, Portland

06519

Kinevant Study Site, New Haven

02115

Kinevant Study Site, Boston

Sponsors
All Listed Sponsors
lead

Kinevant Sciences GmbH

INDUSTRY